(RTTNews) - Arcturus Therapeutics Holdings Inc. (ARCT) fell 55.79% to trade at $10.26, down $12.90, after reporting interim results from its Phase 2 trial of ARCT-032, an inhaled mRNA therapy for cystic fibrosis.
The trial showed the therapy was generally safe and well tolerated, and imaging data revealed mucus-plug reduction in four of six participants; however, lung-function improvements did not meet expectations, contributing to investor disappointment.
On Wednesday, ARCT opened at $23.15, hit a high of $23.90, and a low of $9.85, compared to a previous close of $23.16 on the NASDAQ. Trading volume surged to approximately 50 million shares, far exceeding the average of ~0.7 million. The stock's 52-week range is $8.04 - $37.40.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
